InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.06
(
-0.08%
)
Bitcoin
64,102.51
(
0.15%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: nsomniyak post# 210841

Monday, 04/24/2017 5:45:09 PM

Monday, April 24, 2017 5:45:09 PM

Post# of 251721
Fresenius Kabi acquires AKRX for $34/sh in cash—a 35% premium to AKRX’s latest “unaffected” share price on 4/6/17 (#msg-130304273):

http://finance.yahoo.com/news/fresenius-kabi-acquire-akorn-205800399.html

The nominal deal value (including assumption of debt) is $4.75B. Due to international regulatory approvals, the deal is not expected to close until early 2018.

Fresenius Kabi is a wholly-owned subsidiary of the global healthcare giant, Fresenius SE & Co. KGaA (FRE.DE). (FMS, the dialysis company, is 31% owned by FRE.DE.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up